Cyclacel Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, CYCC, Cyclacel Pharmaceuticals Inc, priceseries

Cyclacel Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
3.50
Close
3.32
High
3.50
Low
3.30
Previous Close
3.50
Daily Price Gain
-0.18
YTD High
4.53
YTD High Date
Jan 3, 2022
YTD Low
2.76
YTD Low Date
Jan 24, 2022
YTD Price Change
-1.13
YTD Gain
-25.39%
52 Week High
8.95
52 Week High Date
Mar 15, 2021
52 Week Low
2.76
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-2.73
52 Week Gain
-45.12%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 31. 2017
73.60
Apr 13. 2017
118.15
9 Trading Days
60.53%
Link
LONG
Sep 12. 2017
37.60
Sep 13. 2017
40.10
1 Trading Days
6.65%
Link
LONG
Nov 15. 2017
33.60
Nov 29. 2017
36.62
9 Trading Days
8.99%
Link
LONG
Sep 4. 2018
31.40
Sep 5. 2018
34.40
1 Trading Days
9.55%
Link
LONG
Dec 6. 2019
11.90
Dec 11. 2019
12.62
3 Trading Days
6.09%
Link
LONG
Jan 6. 2020
13.50
Jan 13. 2020
14.70
5 Trading Days
8.89%
Link
LONG
May 19. 2020
4.37
May 29. 2020
5.09
7 Trading Days
16.47%
Link
LONG
Dec 22. 2020
6.40
Dec 31. 2020
7.03
6 Trading Days
9.88%
Link
LONG
Jan 6. 2021
7.93
Jan 15. 2021
8.33
7 Trading Days
5.04%
Link
LONG
Feb 4. 2021
7.65
Feb 18. 2021
8.47
9 Trading Days
10.75%
Link
LONG
May 14. 2021
6.79
May 24. 2021
7.28
6 Trading Days
7.23%
Link
LONG
Aug 23. 2021
4.92
Sep 10. 2021
5.62
13 Trading Days
14.25%
Link
Company Information
Stock Symbol
CYCC
Exchange
NasdaqCM
Company URL
http://www.cyclacel.com
Company Phone
908-517-7330
CEO
Spiro Rombotis
Headquarters
New Jersey
Business Address
200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS, NJ 07922
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001130166
About

Cyclacel Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders. Its lead candidate, sapacitabine, oral nucleoside analogue prodrug that acts through a novel mechanism. It also develops Seliciclib and CYC065-Second Generation CDK Inhibitor. The company was founded by Ronald J. Berenson, David Philip Lane and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Description

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; in Phase II clinical trial for myelodysplastic syndromes; and in Phase I/II clinical trial in combination with seliciclib, a drug candidate to treat solid tumors. Its oncology development programs also comprise Seliciclib, an oral inhibitor of cyclin dependent kinase (CDK) 2/9 enzymes, which are central to the process of cell division and cell cycle control that has completed a Phase IIb clinical trial; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial targeting CDK2/9 enzymes with potential utility in hematological malignancies and solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage; and Aurora Kinase inhibitors, a serine/threonine protein kinases that focuses on cell division or mitosis for the treatment of cancer. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading